PROJECT Brief  

Bicara Therapeutics is a clinical-stage biotech company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. Their focus is on Head & Neck Cancer treatment, with their Ficerafusp alfa (BCA101) bifunctional EGFR/TGF-β antibody, currently in clinical development.